Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital)

N/A

Report date: 2024/11/20 20:00:31

Base Information

Drug NameDual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital)
Drug Alias NameUniversal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Universal CAR-TCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapy +[5] 
Mechanisms of ActionT lymphocyte replacementsAnti-CD19Anti-CD20 +[4] 
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20CD22
Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesPla General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPla General Hospital
Active IndicationsN/A
Inactive IndicationsLymphoma, B-CellLeukemia, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A